20/20 Biolabs, Inc. (AIDX) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-06

Key Insights

The reporting person, Jiming Zhou, acquired 150,000 stock options in 20/20 Biolabs, Inc. (ticker AIDX) on April 2, 2026 with an exercise price of $1.88 and a 10-year expiration date.
This insider transaction suggests that Jiming Zhou, the Chief Operating Officer, is bullish on the company's future prospects and is aligning his interests with shareholders through this equity grant.
The timing and size of the option grant, representing a significant stake, indicate that the company may be positioning for potential growth or other strategic initiatives.

Want the newest filings?

This analysis covers the filing from 2026-04-06. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-04-06

Alan B. Bergman, the Chief Financial Officer of 20/20 Biolabs, Inc. (AIDX), was granted 100,000 stock options at an exercise price of $1.88 per share, vesting over 4 years.
This indicates that the company is incentivizing its executive team through equity-based compensation, which can align their interests with those of shareholders.
The relatively large option grant size of 100,000 shares suggests that the company and board view Bergman as a key contributor to the company's future success.

Other reports for 20/20 Biolabs, Inc.

Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.